A risk assessment of automated treatment planning and recommendations for clinical deployment.

FMEA automated treatment planning external beam radiation therapy quality assurance risk analysis

Journal

Medical physics
ISSN: 2473-4209
Titre abrégé: Med Phys
Pays: United States
ID NLM: 0425746

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 07 02 2019
revised: 04 04 2019
accepted: 05 04 2019
pubmed: 20 4 2019
medline: 23 11 2019
entrez: 20 4 2019
Statut: ppublish

Résumé

To assess the risk of failure of a recently developed automated treatment planning tool, the radiation planning assistant (RPA), and to determine the reduction in these risks with implementation of a quality assurance (QA) program specifically designed for the RPA. We used failure mode and effects analysis (FMEA) to assess the risk of the RPA. The steps involved in the workflow of planning a four-field box treatment of cervical cancer with the RPA were identified. Then, the potential failure modes at each step and their causes were identified and scored according to their likelihood of occurrence, severity, and likelihood of going undetected. Additionally, the impact of the components of the QA program on the detectability of the failure modes was assessed. The QA program was designed to supplement a clinic's standard QA processes and consisted of three components: (a) automatic, independent verification of the results of automated planning; (b) automatic comparison of treatment parameters to expected values; and (c) guided manual checks of the treatment plan. A risk priority number (RPN) was calculated for each potential failure mode with and without use of the QA program. In the RPA automated treatment planning workflow, we identified 68 potential failure modes with 113 causes. The average RPN was 91 without the QA program and 68 with the QA program (maximum RPNs were 504 and 315, respectively). The reduction in RPN was due to an improvement in the likelihood of detecting failures, resulting in lower detectability scores. The top-ranked failure modes included incorrect identification of the marked isocenter, inappropriate beam aperture definition, incorrect entry of the prescription into the RPA plan directive, and lack of a comprehensive plan review by the physician. Using FMEA, we assessed the risks in the clinical deployment of an automated treatment planning workflow and showed that a specialized QA program for the RPA, which included automatic QA techniques, improved the detectability of failures, reducing this risk. However, some residual risks persisted, which were similar to those found in manual treatment planning, and human error remained a major cause of potential failures. Through the risk analysis process, we identified three key aspects of safe deployment of automated planning: (a) user training on potential failure modes; (b) comprehensive manual plan review by physicians and physicists; and (c) automated QA of the treatment plan.

Identifiants

pubmed: 31002389
doi: 10.1002/mp.13552
pmc: PMC6561826
mid: NIHMS1024819
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2567-2574

Subventions

Organisme : NCI NIH HHS
ID : UH2 CA202665
Pays : United States
Organisme : NCI NIH HHS
ID : UH3 CA202665
Pays : United States
Organisme : NIH HHS
ID : UH2-CA202665
Pays : United States
Organisme : NIH HHS
ID : UH3-CA202665
Pays : United States

Informations de copyright

© 2019 The Authors. Medical Physics published by Wiley Periodicals, Inc. on behalf of American Association of Physicists in Medicine.

Références

J Appl Clin Med Phys. 2009 Feb 11;10(1):2855
pubmed: 19223834
J Appl Clin Med Phys. 2009 Jan 27;10(1):2905
pubmed: 19223840
Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):852-8
pubmed: 19409731
Med Phys. 2012 Mar;39(3):1542-51
pubmed: 22380386
Radiat Oncol. 2013 May 24;8:127
pubmed: 23705626
J Appl Clin Med Phys. 2013 Sep 06;14(5):265-77
pubmed: 24036868
Pract Radiat Oncol. 2013 Jul-Sep;3(3):157-163
pubmed: 24674359
Med Phys. 2014 Jun;41(6):061709
pubmed: 24877804
Pract Radiat Oncol. 2014 Nov-Dec;4(6):358-67
pubmed: 25407855
Med Phys. 2016 Jul;43(7):4209
pubmed: 27370140
Med Phys. 2017 Sep;44(9):4415-4425
pubmed: 28419482
Pract Radiat Oncol. 2018 Jan - Feb;8(1):e17-e26
pubmed: 28967578
J Vis Exp. 2018 Apr 11;(134):
pubmed: 29708544
J Glob Oncol. 2019 Jan;5:1-9
pubmed: 30629457

Auteurs

Kelly Kisling (K)

Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Jennifer L Johnson (JL)

Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Hannah Simonds (H)

Division of Radiation Oncology, Stellenbosch University and Tygerberg Hospital, Cape Town, 7505, South Africa.

Lifei Zhang (L)

Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Anuja Jhingran (A)

Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Beth M Beadle (BM)

Department of Radiation Oncology - Radiation Therapy, Stanford University, Stanford, CA, 94305, USA.

Hester Burger (H)

Division of Medical Physics, University of Cape Town and Groote Schuur Hospital, Cape Town, 8000, South Africa.

Monique du Toit (M)

Division of Medical Physics, Stellenbosch University and Tygerberg Hospital, Cape Town, 7505, South Africa.

Nanette Joubert (N)

Division of Medical Physics, University of Cape Town and Groote Schuur Hospital, Cape Town, 8000, South Africa.

Remigio Makufa (R)

Department of Medical Physics, Gaborone Private Hospital, Gaborone, Botswana.

William Shaw (W)

Department of Medical Physics (G68), University of the Free State, Bloemfontein, 9301, South Africa.

Christoph Trauernicht (C)

Division of Medical Physics, Stellenbosch University and Tygerberg Hospital, Cape Town, 7505, South Africa.

Peter Balter (P)

Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Rebecca M Howell (RM)

Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Kathleen Schmeler (K)

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Laurence Court (L)

Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH